LeMaitre insider acquires dividend-share rights

Q: What did LMAT insider David B. Roberts report on September 3, 2026?

He reported nine acquisitions of Dividend Equivalent Rights on September 3, 2026. Each grant relates to an existing restricted stock unit or performance share unit award and represents the economic equivalent of one LMAT common share, vesting proportionately with the underlying award.

Q: What securities are involved in this LMAT Form 4 filing?

The filing reports Dividend Equivalent Rights, each stated as the economic equivalent of one share of LeMaitre Vascular common stock. These rights accrued on prior restricted stock unit and performance share unit awards and will vest in step with those awards.

Q: How many Dividend Equivalent Rights were granted in the largest LMAT transaction?

The largest individual grant reported was 5.2874 Dividend Equivalent Rights, tied to a restricted stock unit award granted on December 10, 2025. Like the other grants, each right is economically equivalent to one LMAT common share and vests proportionately with that award.

Q: Were any LMAT shares sold by David B. Roberts in this Form 4?

No. The Form 4 reports only acquisitions of Dividend Equivalent Rights and no sales or dispositions of LMAT common stock or related derivatives. All transactions carry an acquisition code and a zero dollar per-right price.

Q: Are these LMAT insider transactions under a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 checkbox is not checked, and there is no footnote indicating that these acquisitions of Dividend Equivalent Rights were made under a Rule 10b5-1 or other pre-arranged trading plan.

Q: What prior LMAT awards did these Dividend Equivalent Rights accrue on?

The rights accrued on awards originally granted on December 12, 2022, December 8, 2023, December 6, 2024, February 18, 2025, and December 10, 2025. Each set is tied to either a restricted stock unit award or a performance share unit award, as specified in the footnotes.

LMAT’s president and director reported nine small dividend-equivalent accruals tied to prior equity awards, with no sales and no 10b5-1 plan.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

LEMAITRE VASCULAR INC (LMAT) reported that President and Director David B. Roberts received nine small grants of Dividend Equivalent Rights on September 3, 2026. These rights accrued on previously granted restricted stock unit and performance share unit awards and vest proportionately with those awards. Each dividend equivalent right is the economic equivalent of one share of common stock, carries no cash exercise price, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 24.9076 shares

Grant/Award 9 txns

Insider Roberts David B

Role President and Director

Type	Security	Shares	Price	Value
Grant/Award	Dividend Equivalent Rights ^F1	2.1262	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights ^F2	2.1262	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights ^F3	3.6322	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights ^F4	4.3524	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights ^F5	3.1566	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights ^F6	3.5757	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights ^F7	0.3056	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights ^F8	0.3453	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights ^F9	5.2874	$0.00	$0.00

Holdings After Transaction: Dividend Equivalent Rights — 166.8772 contracts (Direct)

Footnotes (9)

F1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F2. These dividend equivalent rights accrued on a performance share unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F4. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F6. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F7. These dividend equivalent rights accrued on a restricted stock unit award granted on 2/18/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F8. These dividend equivalent rights accrued on a performance share unit award granted on 2/18/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F9. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

Key Figures

Dividend Equivalent Rights granted (RSU 12/12/2022): 2.1262 rights Dividend Equivalent Rights granted (PSU 12/12/2022): 2.1262 rights Dividend Equivalent Rights granted (RSU 12/8/2023): 3.6322 rights +5 more

8 metrics

Dividend Equivalent Rights granted (RSU 12/12/2022) 2.1262 rights Accrued on restricted stock unit award granted on December 12, 2022; each right equals one LMAT common share economically

Dividend Equivalent Rights granted (PSU 12/12/2022) 2.1262 rights Accrued on performance share unit award granted on December 12, 2022; each right equals one LMAT common share economically

Dividend Equivalent Rights granted (RSU 12/8/2023) 3.6322 rights Accrued on restricted stock unit award granted on December 8, 2023; vest proportionately with that award

Dividend Equivalent Rights granted (PSU 12/8/2023) 4.3524 rights Accrued on performance share unit award granted on December 8, 2023; vest proportionately with that award

Dividend Equivalent Rights granted (RSU 12/6/2024) 3.1566 rights Accrued on restricted stock unit award granted on December 6, 2024; each right equals one LMAT common share economically

Dividend Equivalent Rights granted (PSU 12/6/2024) 3.5757 rights Accrued on performance share unit award granted on December 6, 2024; vest proportionately with that award

Dividend Equivalent Rights granted (RSU 12/10/2025) 5.2874 rights Accrued on restricted stock unit award granted on December 10, 2025; each right equals one LMAT common share economically

Reported price per Dividend Equivalent Right $0.0000 All nine acquisition transactions on September 3, 2026 show a zero dollar per-right price

Key Terms

Dividend Equivalent Rights, restricted stock unit award, performance share unit award, economic equivalent

4 terms

Dividend Equivalent Rights financial

"These dividend equivalent rights accrued on a restricted stock unit award"

Dividend equivalent rights are promises that mirror the cash payments shareholders get from a company’s profits, but they are paid to holders of certain awards (like stock options or restricted stock units) rather than to actual shares. Think of them as a paycheck top‑up that matches dividends while the award is not yet a real stock, and they matter to investors because they add to employee compensation costs and potential share dilution, affecting company profitability and per‑share value.

restricted stock unit award financial

"These dividend equivalent rights accrued on a restricted stock unit award"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

economic equivalent financial

"Each dividend equivalent right is the economic equivalent of one share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LMAT insider David B. Roberts report on September 3, 2026?

He reported nine acquisitions of Dividend Equivalent Rights on September 3, 2026. Each grant relates to an existing restricted stock unit or performance share unit award and represents the economic equivalent of one LMAT common share, vesting proportionately with the underlying award.

What securities are involved in this LMAT Form 4 filing?

The filing reports Dividend Equivalent Rights, each stated as the economic equivalent of one share of LeMaitre Vascular common stock. These rights accrued on prior restricted stock unit and performance share unit awards and will vest in step with those awards.

How many Dividend Equivalent Rights were granted in the largest LMAT transaction?

The largest individual grant reported was 5.2874 Dividend Equivalent Rights, tied to a restricted stock unit award granted on December 10, 2025. Like the other grants, each right is economically equivalent to one LMAT common share and vests proportionately with that award.

Were any LMAT shares sold by David B. Roberts in this Form 4?

No. The Form 4 reports only acquisitions of Dividend Equivalent Rights and no sales or dispositions of LMAT common stock or related derivatives. All transactions carry an acquisition code and a zero dollar per-right price.

Are these LMAT insider transactions under a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 checkbox is not checked, and there is no footnote indicating that these acquisitions of Dividend Equivalent Rights were made under a Rule 10b5-1 or other pre-arranged trading plan.

What prior LMAT awards did these Dividend Equivalent Rights accrue on?

The rights accrued on awards originally granted on December 12, 2022, December 8, 2023, December 6, 2024, February 18, 2025, and December 10, 2025. Each set is tied to either a restricted stock unit award or a performance share unit award, as specified in the footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/08/2026 - 04:50 PM EDT Accepted by SEC EDGAR 09/08/2026 - 04:50 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts David B

(Last)

(First)

(Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON

MASSACHUSETTS

01803

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and Director

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Dividend Equivalent Rights	⁽¹⁾	09/03/2026		A		2.1262		⁽¹⁾	⁽¹⁾	Common Stock	2.1262	$0	25.4682	D
Dividend Equivalent Rights	⁽²⁾	09/03/2026		A		2.1262		⁽²⁾	⁽²⁾	Common Stock	2.1262	$0	24.7852	D
Dividend Equivalent Rights	⁽³⁾	09/03/2026		A		3.6322		⁽³⁾	⁽³⁾	Common Stock	3.6322	$0	30.34	D
Dividend Equivalent Rights	⁽⁴⁾	09/03/2026		A		4.3524		⁽⁴⁾	⁽⁴⁾	Common Stock	4.3524	$0	32.3815	D
Dividend Equivalent Rights	⁽⁵⁾	09/03/2026		A		3.1566		⁽⁵⁾	⁽⁵⁾	Common Stock	3.1566	$0	17.5403	D
Dividend Equivalent Rights	⁽⁶⁾	09/03/2026		A		3.5757		⁽⁶⁾	⁽⁶⁾	Common Stock	3.5757	$0	18.6239	D
Dividend Equivalent Rights	⁽⁷⁾	09/03/2026		A		0.3056		⁽⁷⁾	⁽⁷⁾	Common Stock	0.3056	$0	1.9861	D
Dividend Equivalent Rights	⁽⁸⁾	09/03/2026		A		0.3453		⁽⁸⁾	⁽⁸⁾	Common Stock	0.3453	$0	2.0893	D
Dividend Equivalent Rights	⁽⁹⁾	09/03/2026		A		5.2874		⁽⁹⁾	⁽⁹⁾	Common Stock	5.2874	$0	13.6627	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a performance share unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

6. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

7. These dividend equivalent rights accrued on a restricted stock unit award granted on 2/18/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

8. These dividend equivalent rights accrued on a performance share unit award granted on 2/18/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

9. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Douglas G. Bush, Attorney-in-fact	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR